Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Transcenta of China Raises $105 Million to Develop Antibody Drugs

publication date: Dec 23, 2020

China's Transcenta Holding completed a $105 million funding round to support its global antibody drug development operations as it advances toward commercial stage. The company's lead asset is TST001, a CLDN18.2 targeting antibody that has started US and China clinical trials. The company has a discovery center in Suzhou and a manufacturing facility in Hangzhou, plus clinical offices in China and the US. In January, Transcenta completed a $100 million Series B+ financing to develop its portfolio, which includes 10 innovative molecules in oncology, bone disorders and nephrology. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021